ReviewFrontiers in psychiatry2026
Implication of orexin transmission in chronic stress, hyperarousal, and neuroplasticity deficits: a mechanistic framework for depression and anxiety.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Stress is a major risk factor for depression- and anxiety-related disorders and produces neuroplastic adaptations within brain regions that regulate emotion, cognition, and stress responsivity. These adaptations include dendritic retraction in the medial prefrontal cortex (mPFC), suppression of plasticity and neurogenesis in the hippocampus (HIPP), and hypertrophic remodeling of circuits within the amygdala (AMY), promoting emotional dysregulation and maladaptive behavior. Although these alterations are well-documented, the mechanisms that coordinate their emergence across multiple neural systems remain unknown. The orexin (OX; hypocretin) system is anatomically and functionally positioned to serve as a key mediator of stress-induced neuroplasticity. Indeed, OX neurons receive direct corticotropin-releasing factor (CRF) input from the hypothalamic paraventricular nucleus (PVN) and project broadly to brain regions involved in arousal, motivation, emotional regulation, and reward processing (e.g., mPFC, HIPP, and AMY). Chronic activation of CRF-sensitive OX pathways may therefore sustain OX-dependent hyperarousal beyond the presence of an acute stressor, increasing excitatory drive throughout emotion-regulation circuits. This prolonged activation may contribute to maladaptive plasticity through alterations in neuronal excitability, impaired homeostatic regulation, and reductions in brain-derived neurotrophic factor (BDNF)-related signaling. In this review, we propose a mechanistic framework in which CRF-mediated recruitment of hypothalamic OX neurons contributes to neuroplasticity deficits in the mPFC, HIPP, and AMY. We discuss how developmental stage, biological sex, and genetic variation influence vulnerability to these adaptations and examine therapeutic strategies aimed at reducing hyperarousal and restoring neural plasticity. Collectively, this theoretical framework positions OX transmission as a potential link between chronic stress and mood-related psychopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.